Nucryst Pharmaceuticals   Report issue

For profit Phase 2
Founded: Princeton NJ United States (1997)
Status: Left NME R&D (2013)

Organization Overview

First Clinical Trial
2003
NCT00076375
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

nanocrystalline silver (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1